Switch to:
Also traded in: Canada, Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt No Debt
QLTI's Cash to Debt is ranked higher than
98% of the 941 Companies
in the Global Biotechnology industry.

( Industry Median: 49.71 vs. QLTI: No Debt )
Ranked among companies with meaningful Cash to Debt only.
QLTI' s Cash to Debt Range Over the Past 10 Years
Min: 0.7  Med: 10000.00 Max: No Debt
Current: No Debt
Interest Coverage No Debt
QLTI's Interest Coverage is ranked higher than
98% of the 367 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. QLTI: No Debt )
Ranked among companies with meaningful Interest Coverage only.
QLTI' s Interest Coverage Range Over the Past 10 Years
Min: 2.58  Med: 10000.00 Max: 9999.99
Current: No Debt
2.58
9999.99
F-Score: 2
Z-Score: 5.03
M-Score: -3.75
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
ROE (%) -27.71
QLTI's ROE (%) is ranked higher than
53% of the 862 Companies
in the Global Biotechnology industry.

( Industry Median: -32.24 vs. QLTI: -27.71 )
Ranked among companies with meaningful ROE (%) only.
QLTI' s ROE (%) Range Over the Past 10 Years
Min: -38.68  Med: -6.58 Max: 51.71
Current: -27.71
-38.68
51.71
ROA (%) -26.78
QLTI's ROA (%) is ranked higher than
51% of the 947 Companies
in the Global Biotechnology industry.

( Industry Median: -27.48 vs. QLTI: -26.78 )
Ranked among companies with meaningful ROA (%) only.
QLTI' s ROA (%) Range Over the Past 10 Years
Min: -17.13  Med: -6.31 Max: 28.78
Current: -26.78
-17.13
28.78
ROC (Joel Greenblatt) (%) -4677.62
QLTI's ROC (Joel Greenblatt) (%) is ranked lower than
80% of the 909 Companies
in the Global Biotechnology industry.

( Industry Median: -360.35 vs. QLTI: -4677.62 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
QLTI' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -3673.87  Med: -59.62 Max: 29.02
Current: -4677.62
-3673.87
29.02
EBITDA Growth (3Y)(%) -17.20
QLTI's EBITDA Growth (3Y)(%) is ranked lower than
66% of the 506 Companies
in the Global Biotechnology industry.

( Industry Median: -2.20 vs. QLTI: -17.20 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
QLTI' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -60.7  Med: -3.90 Max: 87.2
Current: -17.2
-60.7
87.2
EPS Growth (3Y)(%) -10.10
QLTI's EPS Growth (3Y)(%) is ranked lower than
57% of the 501 Companies
in the Global Biotechnology industry.

( Industry Median: -5.20 vs. QLTI: -10.10 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
QLTI' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -47.1  Med: -10.10 Max: 84
Current: -10.1
-47.1
84
» QLTI's 10-Y Financials

Financials (Next Earnings Date: Est. 2016-07-30)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q2 2015

QLTI Guru Trades in Q2 2015

Charles Brandes 153,280 sh (New)
Jim Simons 564,415 sh (+65.36%)
First Eagle Investment Sold Out
» More
Q3 2015

QLTI Guru Trades in Q3 2015

Charles Brandes 181,840 sh (+18.63%)
Jim Simons 376,764 sh (-33.25%)
» More
Q4 2015

QLTI Guru Trades in Q4 2015

Charles Brandes 224,071 sh (+23.22%)
Jim Simons 362,264 sh (-3.85%)
» More
Q1 2016

QLTI Guru Trades in Q1 2016

Charles Brandes 224,071 sh (unchged)
Jim Simons 101,623 sh (-71.95%)
» More
» Details

Insider Trades

Latest Guru Trades with QLTI

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology
Compare:NAS:AKAO, NAS:TENX, NAS:AGLE, NAS:KIN, NAS:TRIL, OTCPK:HSDT, AMEX:CRMD, OTCPK:CWBR, AMEX:PLX, NAS:REPH, NAS:LIFE, NAS:CAPR, NAS:CALA, NAS:NVLS, NAS:CHMA, OTCPK:DMPI, OTCPK:APHQF, NAS:PBMD, NAS:PIRS, OTCPK:COTQF » details
Traded in other countries:QLT.Canada, QLT.Germany,
QLT Inc is a biotechnology company conducts development and commercialization of ocular products that address the unmet medical needs of patients and clinicians.

QLT Inc was formed in 1981 under the laws of the Province of British Columbia. It is a biotechnology company conducts development and commercialization of ocular products that address the unmet medical needs of patients and clinicians. The Company is developing QLT091001, a synthetic retinoid compound for the potential treatment of certain age-related and inherited retinal degenerative diseases. Its competitors include pharmaceutical and biopharmaceutical companies. The research and development, preclinical studies and clinical trials, and ultimately, the manufacturing, marketing and labelling of its products, are subject to extensive regulation by the FDA and other regulatory authorities in the U.S. and other countries.

Ratios

vs
industry
vs
history
P/B 0.60
QLTI's P/B is ranked higher than
96% of the 1017 Companies
in the Global Biotechnology industry.

( Industry Median: 3.34 vs. QLTI: 0.60 )
Ranked among companies with meaningful P/B only.
QLTI' s P/B Range Over the Past 10 Years
Min: 0.2  Med: 0.69 Max: 2.01
Current: 0.6
0.2
2.01
EV-to-EBIT 1.93
QLTI's EV-to-EBIT is ranked higher than
86% of the 280 Companies
in the Global Biotechnology industry.

( Industry Median: 21.76 vs. QLTI: 1.93 )
Ranked among companies with meaningful EV-to-EBIT only.
QLTI' s EV-to-EBIT Range Over the Past 10 Years
Min: -16.3  Med: -0.90 Max: 3.7
Current: 1.93
-16.3
3.7
EV-to-EBITDA 1.96
QLTI's EV-to-EBITDA is ranked higher than
86% of the 305 Companies
in the Global Biotechnology industry.

( Industry Median: 18.58 vs. QLTI: 1.96 )
Ranked among companies with meaningful EV-to-EBITDA only.
QLTI' s EV-to-EBITDA Range Over the Past 10 Years
Min: -9.5  Med: -0.90 Max: 3.8
Current: 1.96
-9.5
3.8
Current Ratio 33.59
QLTI's Current Ratio is ranked higher than
97% of the 913 Companies
in the Global Biotechnology industry.

( Industry Median: 4.50 vs. QLTI: 33.59 )
Ranked among companies with meaningful Current Ratio only.
QLTI' s Current Ratio Range Over the Past 10 Years
Min: 1.1  Med: 19.82 Max: 85.25
Current: 33.59
1.1
85.25
Quick Ratio 33.59
QLTI's Quick Ratio is ranked higher than
97% of the 913 Companies
in the Global Biotechnology industry.

( Industry Median: 4.24 vs. QLTI: 33.59 )
Ranked among companies with meaningful Quick Ratio only.
QLTI' s Quick Ratio Range Over the Past 10 Years
Min: 1.07  Med: 19.49 Max: 85.25
Current: 33.59
1.07
85.25

Valuation & Return

vs
industry
vs
history
Price/Net Cash 0.61
QLTI's Price/Net Cash is ranked higher than
99% of the 691 Companies
in the Global Biotechnology industry.

( Industry Median: 4.99 vs. QLTI: 0.61 )
Ranked among companies with meaningful Price/Net Cash only.
QLTI' s Price/Net Cash Range Over the Past 10 Years
Min: 0.64  Med: 3.08 Max: 64.25
Current: 0.61
0.64
64.25
Price/Net Current Asset Value 0.60
QLTI's Price/Net Current Asset Value is ranked higher than
99% of the 814 Companies
in the Global Biotechnology industry.

( Industry Median: 4.96 vs. QLTI: 0.60 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
QLTI' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 0.35  Med: 2.08 Max: 21.25
Current: 0.6
0.35
21.25
Price/Tangible Book 0.59
QLTI's Price/Tangible Book is ranked higher than
97% of the 945 Companies
in the Global Biotechnology industry.

( Industry Median: 3.98 vs. QLTI: 0.59 )
Ranked among companies with meaningful Price/Tangible Book only.
QLTI' s Price/Tangible Book Range Over the Past 10 Years
Min: 0.27  Med: 1.72 Max: 17.87
Current: 0.59
0.27
17.87
Price/Projected FCF 9.00
QLTI's Price/Projected FCF is ranked lower than
73% of the 182 Companies
in the Global Biotechnology industry.

( Industry Median: 3.56 vs. QLTI: 9.00 )
Ranked among companies with meaningful Price/Projected FCF only.
QLTI' s Price/Projected FCF Range Over the Past 10 Years
Min: 0.21  Med: 1.37 Max: 200
Current: 9
0.21
200
Earnings Yield (Greenblatt) (%) 51.83
QLTI's Earnings Yield (Greenblatt) (%) is ranked higher than
96% of the 1100 Companies
in the Global Biotechnology industry.

( Industry Median: -9.50 vs. QLTI: 51.83 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
QLTI' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 26.9  Med: 47.60 Max: 15143.1
Current: 51.83
26.9
15143.1

More Statistics

EPS (TTM) $ -0.74
Beta-0.20
Short Percentage of Float0.70%
52-Week Range $1.33 - 3.21
Shares Outstanding (Mil)52.83

Analyst Estimate

Dec16 Dec17
Revenue (Mil $)
EPS ($) -0.56 -0.60
EPS w/o NRI ($) -0.56 -0.60
EPS Growth Rate
(3Y to 5Y Estimate)
N/A
» More Articles for QLTI

Headlines

Articles On GuruFocus.com
Weekly CFO Sells Highlight: SWN, BECN, NSIT, HOLX, QLTI, THRX Aug 13 2012 
QLT Inc. Reports Operating Results (10-K) Mar 01 2011 
QLT Inc. (QLTI) CEO Robert Butchofsky buys 3,000 Shares Nov 08 2010 
QLT Inc. Reports Operating Results (10-Q) Nov 03 2010 
QLT Inc. (QLTI) CEO Robert Butchofsky buys 5,000 Shares Jun 23 2010 
QLT Inc. (QLTI) CFO Cameron Nelson buys 10,000 Shares Nov 10 2009 
QLT Inc. Reports Operating Results (10-Q) Nov 06 2009 
QLT Inc. (QLTI) CEO Robert Butchofsky buys 10,000 Shares Nov 04 2009 
QLT Inc. Reports Operating Results (10-Q) Aug 06 2009 
100 Mile Diet Idea #1: QLT Inc -- a Cigar Butt with Legs? May 20 2009 

More From Other Websites
QLT INC/BC Files SEC form 8-K, Change in Directors or Principal Officers, Submission of Matters to a... Jun 23 2016
QLT Announces Results of Annual General Meeting of Shareholders Jun 17 2016
QLT Announces Results of Annual General Meeting of Shareholders Jun 17 2016
QLT INC/BC Files SEC form 8-K/A, Other Events, Financial Statements and Exhibits Jun 17 2016
Aegerion, QLT Ink Merger Deal to Form Novelion Therapeutics Jun 16 2016
QLT INC/BC Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and... Jun 16 2016
[video]Wall Street Loses Gains After Fed's Unsurprising June Call Jun 15 2016
Stocks Turn Lower After Yellen Expresses Confidence in U.S. Economy Jun 15 2016
6 Biopharma Movers Making a Run on Wednesday Jun 15 2016
Wall Street Rises as It Awaits Fed, Crude Comes Off Lows Jun 15 2016
Why Aegerion Pharmaceuticals, Bank of America and Three Other Stocks are in Spotlight Today? Jun 15 2016
Stock Futures Hold Gains as Industrial Production Falls Jun 15 2016
Aegerion And QLT Agree To Merge Jun 15 2016
Aegerion Pharmaceuticals and QLT Inc. Agree to Strategic Merger Jun 15 2016
QLT, Aegerion Merge Two Troubled Biotechs Jun 15 2016
QLT INC/BC Files SEC form 8-K, Other Events, Financial Statements and Exhibits Jun 15 2016
Aegerion and QLT announce merger plans Jun 15 2016
Aegerion Pharmaceuticals and QLT Inc. Agree to Strategic Merger Jun 15 2016
QLT, Inc. :QLTI-US: Earnings Analysis: Q1, 2016 By the Numbers : June 8, 2016 Jun 08 2016
Most Popular Healthcare Stocks Under $5 May 31 2016
QLT INC/BC Financials May 13 2016
QLT INC/BC Files SEC form 8-K, Other Events, Financial Statements and Exhibits May 05 2016
QLT Inc. reports 1Q loss May 05 2016
QLT Inc. reports 1Q loss May 05 2016
QLT Announces First Quarter 2016 Results May 05 2016
QLT Announces First Quarter 2016 Results May 05 2016
QLT Terminates $20 Million Private Placement May 02 2016
QLT Inc. Completes Enrollment in its Natural History Study Apr 22 2016
QLT Announces Date of Special Distribution to Shareholders Apr 04 2016
QLT Provides Update on Special Distribution to Shareholders Mar 21 2016
QLT Inc. reports 4Q loss Feb 25 2016
QLT Announces Results of Annual Meeting of Shareholders Jan 12 2016
QLT Calls Special Meeting of Its Shareholders in Connection With Aralez Pharmaceuticals Transaction Dec 28 2015
QLT Commences Breach of Contract Action Against Valeant Pharmaceuticals Dec 16 2015
QLT, Deerfield and Other Leading Healthcare Investors Confirm Their Planned Investment in Aralez... Dec 07 2015
QLT Inc. reports 3Q loss Oct 29 2015
QLT Announces Third Quarter 2015 Results Oct 29 2015
QLT Announces Termination of Merger Agreement With InSite Vision Sep 15 2015
QLT Provides Additional Update on Its Proposed Acquisition of InSite Vision Incorporated Sep 04 2015
InSite Vision Determines that an Unsolicited Offer from a Global Pharmaceutical Company to Acquire... Sep 04 2015
QLT Provides Further Update on Its Proposed Acquisition of InSite Vision Incorporated Sep 03 2015
QLT and InSite Vision Agree on Amended and Restated Merger Agreement Aug 27 2015
InSite Vision and QLT Amend Merger Agreement Aug 27 2015
InSite Vision Determines that an Unsolicited Offer from a Multi-National Pharmaceutical Company to... Aug 21 2015
QLT Provides Update on Its Proposed Acquisition of InSite Vision Incorporated Aug 21 2015
QLT Inc. reports 2Q loss Jul 30 2015
Auxilium Pharma rejects Endo's takeover offer Sep 22 2014
Auxilium to combine with eye drug maker QLT Jun 26 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)